Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Transcode Therapeutics, Inc.RNAZ · Entity 8499 | Chief Technology Officer · 10% owner | December 12, 2022 | December 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Transcode Therapeutics, Inc.
Report date December 12, 2022 · Filed December 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.56 · Expires 2027-12-11 | Direct | 60,000 |
Reported balance
After 2022-12-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-12 · Grant · Acquired 60,000 · Balance 60,000 F1: Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (December 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (December 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2022 Filed Dec 14, 2022 20:10 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001104659-22-127083 · tm2232745-3_4seq1.xml · derivative · entry 1 Medarova Zdravka · CIK 0001855758 · Chief Technology Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (December 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date. Read SEC document |
| February 01, 2022 Filed Dec 14, 2022 20:06 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-22-127082 · tm2232745-4_4seq1.xml · derivative · entry 1 Medarova Zdravka · CIK 0001855758 · Chief Technology Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2027-01-31 F1 · derivative.exercise_date: Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-seven percent (67%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.